Literature DB >> 15699701

Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease.

Meena Thayu1, Jonathan E Markowitz, Petar Mamula, Pierre A Russo, William I Muinos, Robert N Baldassano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15699701     DOI： 10.1097/00005176-200502000-00026

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN： 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  23 in total

1.  Long-term durability of Crohn's disease treatment with infliximab.

Authors:  Stephen J Rudolph; David I Weinberg; Robert P McCabe
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

Review 2.  Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.

Authors:  Meenakshi Bewtra; James D Lewis
Journal:  Expert Rev Clin Immunol       Date:  2010-07       Impact factor: 4.473

3.  Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.

Authors:  Hélène Théophile; Thierry Schaeverbeke; Ghada Miremont-Salamé; Abdelilah Abouelfath; Valentine Kahn; Françoise Haramburu; Bernard Bégaud
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

4.  Mucinous carcinoma in Crohn's disease originating in a fistulous tract.

Authors:  Hugh J Freeman; Tom Perry; Douglas L Webber; Silvia D Chang; Mong-Yang Loh
Journal:  World J Gastrointest Oncol       Date:  2010-07-15

5.  Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.

Authors:  Eric D Shah; Elliot S Coburn; Anil Nayyar; Kerry Jo Lee; Jenna L Koliani-Pace; Corey A Siegel
Journal:  Aliment Pharmacol Ther       Date:  2020-01-28       Impact factor: 8.171

6.  Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.

Authors:  Mariko Yabe; L Jeffrey Medeiros; Yahya Daneshbod; Masoud Davanlou; Carlos E Bueso-Ramos; Elisa J Moran; Ken H Young; Roberto N Miranda
Journal:  Ann Diagn Pathol       Date:  2016-10-18       Impact factor: 2.090

7.  Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.

Authors:  G S Falchook; F Vega; N H Dang; F Samaniego; M A Rodriguez; R E Champlin; C Hosing; S Verstovsek; B Pro
Journal:  Ann Oncol       Date:  2009-02-23       Impact factor: 32.976

8.  T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary.

Authors:  Lindsay A Schmidt; Megan S Lim
Journal:  J Hematop       Date:  2009-03-18       Impact factor: 0.196

Review 9.  Review and clinical perspectives for the use of infliximab in ulcerative colitis.

Authors:  R Panaccione; R N Fedorak; G Aumais; Edmond-Jean Bernard; C N Bernstein; A Bitton; K Croitoru; L A Dieleman; R Enns; B G Feagan; D Franchimont; G R Greenberg; Anne-Marie Griffiths; J K Marshall; P Pare; S Patel; R Penner; C Render; E Seidman; A Hillary Steinhart
Journal:  Can J Gastroenterol       Date:  2008-03       Impact factor: 3.522

Review 10.  Managing Crohn disease in children and adolescents : focus on tumor necrosis factor antagonists.

Authors:  Shehzad A Saeed; Wallace V Crandall
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.